gout
Information
- Disease name
- gout
- Disease ID
- DOID:13189
- Description
- "An arthritis that has_material_basis_in uric acid crystal deposits located_in joint." [url:http\://en.wikipedia.org/wiki/Gout, url:http\://www.mayoclinic.com/health/gout/DS00090, url:http\://www.nlm.nih.gov/medlineplus/ency/article/000422.htm]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04956432 | Active, not recruiting | Phase 3 | A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout | June 15, 2021 | July 17, 2024 |
| NCT04746989 | Active, not recruiting | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol | February 1, 2021 | December 31, 2023 | |
| NCT04125459 | Active, not recruiting | Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout | January 22, 2020 | March 3, 2024 | |
| NCT05006001 | Active, not recruiting | Evaluation of Colchicine and Nonsteroidal Anti-inflammatory Drug Combination Therapy and Renal Function in Gout Patients | January 1, 2012 | December 31, 2024 | |
| NCT05289544 | Active, not recruiting | N/A | Phone-Based Based Walk With Ease Program for Adults With Arthritis | April 1, 2022 | September 29, 2024 |
| NCT05253833 | Active, not recruiting | Phase 2 | Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout | August 12, 2022 | August 2024 |
| NCT00174967 | Completed | Phase 2 | Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout | January 2001 | July 2001 |
| NCT00175006 | Completed | Validation Study of Physical Measurement of Tophi | November 2002 | January 2003 | |
| NCT00175019 | Completed | Phase 3 | Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 | July 2003 | February 2007 |
| NCT00325195 | Completed | Phase 3 | Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout | May 2006 | December 2007 |
| NCT00430248 | Completed | Phase 3 | Efficacy and Safety of Oral Febuxostat in Participants With Gout | February 2007 | March 2008 |
| NCT00506883 | Completed | Phase 3 | MPC-004 for the Treatment of an Acute Gout Flare | April 2007 | October 2007 |
| NCT00584311 | Completed | N/A | MRI and Ultrasound Findings in Patients With Gout and Normal Plain Radiographs | June 2007 | May 2008 |
| NCT00610363 | Completed | Phase 2 | Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares | November 2007 | October 2008 |
| NCT00738842 | Completed | Phase 1 | Uric Acid Study in Healthy Male Volunteers | May 2008 | July 2008 |
| NCT00819585 | Completed | Phase 2 | A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study) | December 2008 | August 2010 |
| NCT00821392 | Completed | Phase 3 | Phase III Trial of Febuxostat in Korea Gout Patients | August 2006 | September 2007 |
| NCT00856206 | Completed | Phase 3 | Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE) | March 2009 | January 2011 |
| NCT00958438 | Completed | Phase 3 | PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2) | July 2009 | December 2010 |
| NCT00985127 | Completed | Phase 2 | Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout | September 2009 | September 2010 |
| NCT00995618 | Completed | Phase 2 | Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia | September 2009 | April 2010 |
| NCT01001338 | Completed | Phase 2 | Allopurinol Combination Study | October 2009 | August 2016 |
| NCT01052987 | Completed | Phase 2 | Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia | January 2010 | November 2010 |
| NCT01112982 | Completed | Phase 4 | An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. | May 2010 | December 2014 |
| NCT01129648 | Completed | Phase 2 | Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout | May 2010 | November 2010 |
| NCT01151709 | Completed | Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management | August 2010 | February 2012 | |
| NCT01265264 | Completed | Phase 2 | Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol | December 2010 | February 2013 |
| NCT01310673 | Completed | Phase 4 | Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout | January 1998 | July 2009 |
| NCT01312727 | Completed | N/A | Hereditary Tubulointerstitial Nephritis | November 2010 | July 2016 |
| NCT01336686 | Completed | Phase 2 | Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout | May 2011 | November 2011 |
| NCT01356498 | Completed | Phase 3 | Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout | December 2006 | January 2010 |
| NCT01361646 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 | June 2011 | January 2013 |
| NCT01363869 | Completed | N/A | Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals | June 2011 | March 2013 |
| NCT01391325 | Completed | Phase 4 | Allopurinol Outcome Study | July 2011 | March 2013 |
| NCT01399008 | Completed | Phase 2 | Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients | June 2011 | February 2012 |
| NCT01407874 | Completed | Phase 2 | A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency | September 2011 | July 2012 |
| NCT01416402 | Completed | Phase 2 | Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients | August 2011 | October 2011 |
| NCT01472692 | Completed | Phase 4 | Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure | October 2011 | March 2014 |
| NCT01477346 | Completed | N/A | Arthritis Research UK Gout Treatment Trial - Phase 2 | March 2013 | October 2016 |
| NCT01493531 | Completed | Phase 3 | Combining Lesinurad With Allopurinol in Inadequate Responders | December 2011 | July 2014 |
| NCT01508702 | Completed | Phase 3 | Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors | January 2012 | November 2013 |
| NCT01510158 | Completed | Phase 3 | Combining Lesinurad With Allopurinol in Inadequate Responders | January 2012 | August 2014 |
| NCT01529099 | Completed | Phase 4 | Postmarketing Study to Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM | January 2009 | July 2015 |
| NCT01549210 | Completed | Italian Observational Study Assessing the Impact of Gout on Patients Disability and Quality of Life | April 2011 | March 2013 | |
| NCT01563432 | Completed | Phase 1 | Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers | January 2012 | February 2012 |
| NCT04812886 | Completed | N/A | Epidemiology of Gout in French Polynesia | April 29, 2021 | August 16, 2021 |
| NCT00102440 | Completed | Phase 3 | Febuxostat Versus Allopurinol Control Trial in Subjects With Gout | July 2002 | February 2004 |
| NCT00111657 | Completed | Phase 2 | Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout | December 2004 | July 2009 |
| NCT00174915 | Completed | Phase 3 | Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. | February 2003 | April 2004 |
| NCT00174941 | Completed | Phase 2 | Long-Term Safety of Febuxostat in Subjects With Gout. | March 2001 | December 2006 |
| NCT00174954 | Completed | Magnetic Resonance Imaging in Subjects With Gouty Tophi | March 2002 | January 2003 | |
| NCT02113111 | Completed | Effects of Fasting on Self Efficacy | April 2014 | September 2015 | |
| NCT02128490 | Completed | Phase 2 | Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment | May 2014 | October 2015 |
| NCT02139046 | Completed | Phase 3 | Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout | April 2014 | November 2015 |
| NCT02219516 | Completed | Phase 1 | Mild, Moderate and Severe Renal Impairment Study | August 1, 2014 | May 13, 2016 |
| NCT02246673 | Completed | Phase 2 | RDEA3170 and Febuxostat Combination Study in Gout Subjects | October 2014 | February 2016 |
| NCT02252835 | Completed | Phase 2 | Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout | August 2014 | December 2014 |
| NCT02279641 | Completed | Phase 1 | RDEA3170 and Allopurinol Combination Study in Gout Subjects | November 1, 2014 | September 11, 2015 |
| NCT02287818 | Completed | Phase 2 | A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout | December 2014 | October 27, 2016 |
| NCT02290210 | Completed | Phase 2 | Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients | July 24, 2014 | August 31, 2015 |
| NCT02330796 | Completed | Phase 2 | Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout | April 2015 | November 2015 |
| NCT02336594 | Completed | Phase 1 | RDEA3170 Bioavailability Study | November 2014 | March 2015 |
| NCT02374164 | Completed | Phase 1 | Food Effect Study of Febuxostat XR in Healthy Participants | February 2015 | April 2015 |
| NCT02393560 | Completed | DECT Study in Allopurinol-Treated Gout Patients | April 2015 | October 2016 | |
| NCT02403687 | Completed | Prospective Analgesic Compound Efficacy (PACE) Study | June 2015 | February 2017 | |
| NCT02464605 | Completed | Phase 1 | Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels | May 2015 | July 2016 |
| NCT02471261 | Completed | Elastography as Gouty Arthropathy Outcome (EGO) | May 2015 | March 2017 | |
| NCT02477488 | Completed | Phase 4 | Optimal Administration of Allopurinol in Dialysis Patients | June 2015 | August 2015 |
| NCT02498652 | Completed | Phase 2 | Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects | July 28, 2015 | June 2, 2016 |
| NCT02500641 | Completed | Phase 4 | Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout | August 17, 2015 | May 10, 2017 |
| NCT02557126 | Completed | Phase 2 | Study of URC102 to Assess the Safety and Efficacy in Gout Patients | October 2015 | August 2016 |
| NCT02578394 | Completed | Phase 2/Phase 3 | Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study | April 2016 | January 26, 2022 |
| NCT02579096 | Completed | Phase 4 | CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat | March 6, 2017 | April 15, 2021 |
| NCT02598596 | Completed | Phase 2 | Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect | December 2015 | April 27, 2020 |
| NCT02608710 | Completed | Phase 1 | RDEA3170 PK/PD Study | November 2015 | April 2016 |
| NCT02648269 | Completed | Phase 1 | Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels | December 2015 | December 2016 |
| NCT02741700 | Completed | N/A | SToRytelling to Improve DiseasE Outcomes in GOut: The STRIDE-GO2 Study | May 31, 2017 | August 31, 2021 |
| NCT02790463 | Completed | N/A | Virtual Gout Clinic | January 2013 | October 2018 |
| NCT02855437 | Completed | N/A | Novel Methods for Ascertainment of Gout Flares -A Pilot Study | September 2016 | August 2018 |
| NCT02903446 | Completed | Phase 2 | Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions | February 1, 2017 | March 1, 2020 |
| NCT02950142 | Completed | N/A | Evidence-based Laboratory Test Order Sets in Primary Care | December 1, 2017 | August 1, 2019 |
| NCT03015948 | Completed | Phase 1 | A Single Dose Study of SHR4640 in Healthy Male Volunteers | September 22, 2016 | November 23, 2016 |
| NCT03131583 | Completed | Phase 1 | The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout | February 17, 2017 | January 29, 2018 |
| NCT03162341 | Completed | N/A | Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit | August 10, 2017 | November 8, 2021 |
| NCT03211403 | Completed | Phase 1 | Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level | July 4, 2017 | February 15, 2018 |
| NCT03272425 | Completed | Phase 1 | Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence. | August 14, 2017 | October 4, 2017 |
| NCT03274063 | Completed | N/A | Gout Self-Monitoring Aiming to Reach Target | April 5, 2019 | June 1, 2021 |
| NCT03291782 | Completed | Phase 1 | D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers | September 13, 2017 | August 6, 2018 |
| NCT03345186 | Completed | N/A | A Nurse Led Patient Management Programme to Improve Outcomes in Gout | April 1, 2019 | April 23, 2022 |
| NCT03416543 | Completed | Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis | December 13, 2017 | December 8, 2021 | |
| NCT03470584 | Completed | Vegetarian Diet and Chronic Degenerative Diseases | March 1, 2005 | December 31, 2014 | |
| NCT03569020 | Completed | N/A | The Diet Gout Trial | August 7, 2018 | July 23, 2019 |
| NCT03635957 | Completed | Phase 4 | Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout | September 26, 2018 | October 26, 2020 |
| NCT03650140 | Completed | N/A | Pharmacokinetics and Pharmacodynamics of Anthocyanins | February 1, 2019 | June 6, 2022 |
| NCT03847753 | Completed | Exploring the Comorbidity Between Mental Disorders and General Medical Conditions | January 1, 2000 | January 31, 2020 | |
| NCT03906006 | Completed | Phase 1 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects | October 17, 2018 | June 20, 2019 |
| NCT03927677 | Completed | Phase 1 | The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults. | November 5, 2019 | November 26, 2019 |
| NCT03934099 | Completed | Phase 2 | A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia | December 2, 2019 | May 17, 2021 |
| NCT03994731 | Completed | Phase 4 | Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout | June 13, 2019 | April 11, 2022 |
| NCT04040816 | Completed | Phase 2 | Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients | January 1, 2019 | August 30, 2020 |
| NCT04040907 | Completed | Phase 1 | The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject | November 13, 2019 | May 30, 2021 |
| NCT04052932 | Completed | Phase 3 | A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout | July 16, 2019 | July 14, 2021 |
| NCT04060173 | Completed | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 | September 5, 2019 | February 7, 2020 |
| NCT04066712 | Completed | Phase 1 | Renal PK Study of LC350189 | November 19, 2019 | September 12, 2020 |
| NCT04070846 | Completed | Phase 1 | Mass Balance Study of [14C]LC350189 in Healthy Volunteers | February 26, 2020 | March 7, 2020 |
| NCT04130204 | Completed | Phase 2 | Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS) | February 12, 2020 | May 21, 2021 |
| NCT04139824 | Completed | Phase 1 | The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults | January 22, 2020 | February 25, 2020 |
| NCT04303039 | Completed | Phase 1 | Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects | May 22, 2020 | June 19, 2020 |
| NCT04511702 | Completed | Phase 4 | Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate | October 2, 2020 | March 25, 2024 |
| NCT04519021 | Completed | Knowledge, Attitude and Practice Regarding Diagnosis and Management of Gout Among Clinicians in Nepal | November 1, 2019 | January 31, 2020 | |
| NCT04638543 | Completed | Phase 2 | A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia | November 27, 2020 | October 26, 2021 |
| NCT04776161 | Completed | N/A | Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial | August 2, 2021 | November 10, 2022 |
| NCT04804111 | Completed | Phase 2 | Study of of URC102 to Assess the Efficacy and Safety in Gout Patients | January 21, 2019 | November 29, 2020 |
| NCT00080210 | Completed | Phase 2 | A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy | March 2004 | February 2005 |
| NCT04829435 | Completed | Phase 1 | Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase) | April 21, 2021 | June 1, 2021 |
| NCT04853160 | Completed | Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information | August 15, 2020 | January 5, 2021 | |
| NCT04886050 | Completed | Phase 1 | Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults | July 31, 2021 | December 10, 2021 |
| NCT04900090 | Completed | N/A | Tahiti-families: Polynesian Families of Gout Patients | May 25, 2021 | August 31, 2021 |
| NCT04938024 | Completed | N/A | Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C) | March 28, 2021 | August 30, 2023 |
| NCT04952896 | Completed | Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease | January 1, 2012 | October 29, 2022 | |
| NCT04966325 | Completed | Early Phase 1 | Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects | September 23, 2021 | December 7, 2021 |
| NCT04987242 | Completed | Phase 2 | An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) | July 16, 2021 | March 2, 2022 |
| NCT05007392 | Completed | Phase 3 | A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout | December 21, 2021 | June 14, 2023 |
| NCT05119686 | Completed | Phase 2 | Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients | November 16, 2021 | November 17, 2022 |
| NCT05168683 | Completed | Phase 1 | Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets | January 11, 2022 | February 23, 2022 |
| NCT06189404 | Completed | Phase 1 | Effect of Tigulixostat on the Pharmacokinetics of Theophylline | October 31, 2023 | November 30, 2023 |
| NCT01650246 | Completed | Phase 3 | Open-Label Lesinurad Monotherapy Extension Study in Gout | August 2012 | August 2014 |
| NCT01654276 | Completed | Phase 4 | Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome | May 2012 | March 2015 |
| NCT01685424 | Completed | Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1) | June 30, 2006 | March 1, 2015 | |
| NCT01736514 | Completed | Phase 3 | A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout | March 2011 | February 2012 |
| NCT01744379 | Completed | Phase 1 | Single and Multiple Dose Study in Japanese | December 2012 | May 2013 |
| NCT01808131 | Completed | Phase 3 | Lesinurad and Allopurinol Combination Extension Study in Gout | February 2013 | November 2016 |
| NCT01808144 | Completed | Phase 3 | Lesinurad and Febuxostat Combination Extension Study in Gout | March 1, 2013 | October 6, 2016 |
| NCT01830725 | Completed | Purine Metabolism Enzyme SNP to Uric Acid Production | December 2012 | June 2016 | |
| NCT01872832 | Completed | Phase 1 | Single and Multiple Dose Study in Japanese Subjects | June 2013 | November 2013 |
| NCT01881919 | Completed | Early Phase 1 | Effect of Quercetin Supplements on Healthy Males: a Four-Week Randomized Cross-Over Trial | February 2013 | November 2014 |
| NCT01884272 | Completed | Phase 1 | NSAID Drug Interaction Study | June 2013 | October 2013 |
| NCT01927198 | Completed | Phase 2 | RDEA3170 Monotherapy in Subjects With Gout | August 2013 | July 2014 |
| NCT01988402 | Completed | Phase 4 | Does Allopurinol Prolong a Treated, Acute Gout Flare? | December 2007 | June 2013 |
| NCT01994226 | Completed | Phase 4 | Colchicine Or Naproxen Treatment for ACute gouT | January 2014 | March 2016 |
| NCT02000232 | Completed | Impact of Unapproved Drug Initiative on Colchicine Use | January 2013 | September 2014 | |
| NCT02063997 | Completed | Phase 2 | Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients | March 2014 | January 2015 |
| NCT02082769 | Completed | Phase 3 | Safety and Efficacy of Oral Febuxostat in Subjects With Gout | July 2011 | October 2013 |
| NCT02083510 | Completed | Early Phase 1 | Apolipoprotein CIII Reduction Via Colchicine | February 2014 | May 2014 |
| NCT03336203 | Enrolling by invitation | Phase 4 | The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) | October 30, 2017 | December 31, 2022 |
| NCT06276556 | Enrolling by invitation | Phase 2/Phase 3 | Extension Study of ABP-671 in Participants With Gout | April 22, 2024 | July 2, 2025 |
| NCT06187519 | Not yet recruiting | N/A | UR+AIMS Gout Wearable Skin Uric Acid Monitor Study | September 30, 2024 | February 1, 2028 |
| NCT05507723 | Not yet recruiting | N/A | Tight Control of Gouty Arthritis Compared to Usual Care | October 2024 | December 2027 |
| NCT05473325 | Not yet recruiting | Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY) | January 1, 2023 | June 22, 2025 | |
| NCT05109936 | Not yet recruiting | Phase 3 | Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration | January 1, 2022 | August 1, 2025 |
| NCT05454423 | Not yet recruiting | N/A | Effect of Aquatic Exercise and Traditional Physical Therapy on Gout in Hypertensive Menopausal Women With Hyperuricemia | July 1, 2022 | September 1, 2023 |
| NCT06258213 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers | January 3, 2024 | November 22, 2024 |
| NCT05127772 | Recruiting | Phase 1 | A Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple Dosing | November 22, 2021 | November 25, 2023 |
| NCT03840928 | Recruiting | PatientSpot Formerly Known as ArthritisPower | April 1, 2015 | March 1, 2025 | |
| NCT06298071 | Recruiting | Phase 1 | A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout. | March 3, 2023 | December 30, 2025 |
| NCT05499312 | Recruiting | Phase 2 | An Innovative Chinese Herbal Formula for the Treatment of Gout | October 11, 2022 | February 2025 |
| NCT04075903 | Recruiting | N/A | Gout in the ED and Improving Research Participation | June 1, 2021 | August 31, 2024 |
| NCT05546593 | Recruiting | Prevalence of Abnormalities in Ultrasonography of Joint and Tendons in Patients With Gout | August 24, 2022 | September 2024 | |
| NCT05586958 | Recruiting | Phase 3 | Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients | October 25, 2022 | June 2025 |
| NCT04199325 | Recruiting | N/A | Probiotics for Gout / Hyperuricemia: A Randomized, Intervention, Parallel Controlled, Multicenter Clinical Trial | November 1, 2018 | March 2024 |
| NCT04213534 | Recruiting | The Influence of Urate-lowering Therapy on Sperm Quality of Male Gouty Patients：A Prospective Cohort Study | October 10, 2020 | December 2023 | |
| NCT05586971 | Recruiting | Phase 3 | Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients | March 30, 2023 | December 2025 |
| NCT05607797 | Recruiting | N/A | Genetic of Chronic Kidney Disease and Gout in New Caledonia | March 14, 2023 | August 31, 2024 |
| NCT05658575 | Recruiting | Phase 2/Phase 3 | Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | January 6, 2023 | October 2024 |
| NCT05665699 | Recruiting | Phase 2 | Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout | April 17, 2023 | December 30, 2024 |
| NCT04695028 | Recruiting | CRYSTALILLE Cohort: Getting the Whole Picture of Crystal-related Arthropathies | March 16, 2021 | October 2030 | |
| NCT04733079 | Recruiting | N/A | Treat-to-target by Email During Urate-lowering Therapy in Gout | December 15, 2021 | October 1, 2024 |
| NCT05690204 | Recruiting | Phase 2 | Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. | December 12, 2022 | January 30, 2025 |
| NCT05745727 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels | March 23, 2023 | December 2024 |
| NCT05815901 | Recruiting | Phase 3 | A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients | March 14, 2023 | August 2025 |
| NCT05818085 | Recruiting | Phase 2/Phase 3 | Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout | August 11, 2023 | August 2025 |
| NCT04844814 | Recruiting | Phase 2 | Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation | June 2, 2022 | July 2, 2025 |
| NCT05927688 | Recruiting | Assessment of Physician Consideration of ePRO's, From Patients With Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments | July 18, 2023 | July 2027 | |
| NCT04875702 | Recruiting | Phase 4 | Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout | January 23, 2024 | November 2028 |
| NCT06056570 | Recruiting | Phase 1/Phase 2 | Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia | October 2023 | November 2023 |
| NCT06439602 | Recruiting | Phase 3 | Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients | June 2024 | November 2026 |
| NCT06211322 | Recruiting | N/A | The Remote Monitoring of Gout Feasibility Study | February 27, 2024 | July 2024 |
| NCT03214263 | Recruiting | Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Diseases | May 2015 | December 2024 | |
| NCT06229145 | Recruiting | Phase 4 | A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout | January 22, 2024 | May 31, 2026 |
| NCT06235710 | Recruiting | Prevalence of Musculoskeletal Complaints in Nursing Home Residents | January 18, 2024 | May 1, 2025 | |
| NCT04697602 | Terminated | N/A | Low-dose Colchicine With or Without Stepwise Dose Titration of Febuxostat for Flare Prophylaxis in Gout | January 20, 2021 | August 23, 2023 |
| NCT04839315 | Terminated | Early Phase 1 | COVID-19 Vaccination in Rheumatic Disease Patients | February 15, 2021 | February 9, 2022 |
| NCT04987294 | Terminated | Phase 2 | Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease | September 2, 2022 | September 2, 2022 |
| NCT02462421 | Terminated | Phase 4 | Pharmacogenetics of SGLT2 Inhibitors | June 1, 2015 | December 31, 2021 |
| NCT02187029 | Terminated | Phase 1 | Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects. | July 2014 | December 2014 |
| NCT05256810 | Terminated | Phase 1/Phase 2 | A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout | February 25, 2022 | January 25, 2023 |
| NCT01701622 | Terminated | N/A | The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study | January 2010 | October 2011 |
| NCT03226899 | Terminated | Phase 4 | A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment | July 19, 2017 | February 25, 2019 |
| NCT01459796 | Terminated | Phase 3 | Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares | November 2011 | June 2013 |
| NCT01818505 | Unknown status | The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome | March 2013 | ||
| NCT01038947 | Unknown status | Phase 1 | Safety and Efficacy Study of Intramuscular Uricase-PEG 20 | December 2009 | May 2010 |
| NCT05275348 | Unknown status | N/A | Delivery of Enhance Fitness Trial | February 2, 2022 | January 31, 2024 |
| NCT01021241 | Unknown status | Phase 1 | Safety and Efficacy Study of Intravenous Uricase-PEG 20 | October 2009 | March 2010 |
| NCT05309057 | Unknown status | Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk | November 1, 2020 | August 2022 | |
| NCT05324423 | Unknown status | Phase 1 | To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout | October 18, 2021 | September 1, 2022 |
| NCT04047394 | Unknown status | Phase 1 | A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers | October 22, 2019 | December 30, 2022 |
| NCT02037321 | Unknown status | Meta-Analyses of the Effect of Vegetable Protein for Animal Protein on Cardiometabolic Risk | May 2013 | December 2017 | |
| NCT03601260 | Unknown status | N/A | The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients | August 2018 | December 2018 |
| NCT04897113 | Unknown status | N/A | Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old | May 12, 2021 | December 30, 2022 |
| NCT05065606 | Unknown status | Descriptive Analysis of Dual-energy Computed Tomography Exams of Adult Patients With Gout | November 30, 2016 | November 30, 2021 | |
| NCT03306758 | Unknown status | N/A | The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout | November 1, 2017 | September 30, 2018 |
| NCT01642706 | Unknown status | Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments | July 2, 2012 | December 2020 | |
| NCT03038386 | Unknown status | N/A | Diagnostic Value of DECT Scan Compared to Diagnostic Needle Aspiration | April 2016 | June 2019 |
| NCT04953533 | Unknown status | Research and Development of a New Technology for Detection of Abnormal Excretion of Intestinal Uric Acid Involved in the Incidence of Gout | July 6, 2021 | December 31, 2023 | |
| NCT04808856 | Unknown status | N/A | Treatment of Refractory Gout With ACTH or Methylprednisolone | April 1, 2021 | April 1, 2022 |
| NCT04960527 | Unknown status | N/A | Acute Effects of Tart Cherry on Uric Acid and Biomarkers of CVD Risk in Healthy Individuals | July 10, 2021 | January 30, 2022 |
| NCT01363791 | Unknown status | Meta-analyses of Fructose and Cardiometabolic Risk | May 2009 | March 2016 | |
| NCT02702479 | Unknown status | Meta-analyses of the Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk | June 2014 | June 2016 | |
| NCT02716870 | Unknown status | Meta-analyses of the Effect of Important Food Sources of Sugars on Cardiometabolic Risk Factors | June 2015 | December 2020 | |
| NCT01608620 | Unknown status | Meta-analyses of Total and Individual Fructose-containing Sugars and Incident Cardiometabolic Disease | May 2012 | September 2016 | |
| NCT04224662 | Unknown status | A Pilot Study to Explore the Role of Gut Flora in Gout | March 2, 2020 | July 2023 | |
| NCT03388515 | Unknown status | Phase 1 | A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects. | October 9, 2017 | January 31, 2020 |
| NCT01519687 | Unknown status | Phase 2 | Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout | January 2012 | June 2012 |
| NCT02702375 | Unknown status | Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases | September 2015 | September 2018 | |
| NCT02230943 | Unknown status | Rheumatology Informatics System for Effectiveness | April 2014 | ||
| NCT04072471 | Withdrawn | Post-Authorisation Safety Study of Lesinurad | January 29, 2021 | June 30, 2023 | |
| NCT01418781 | Withdrawn | CLinical Prediction Rule Score in Veterans | January 2008 | March 2010 | |
| NCT04459936 | Withdrawn | N/A | Urica Cor Intervention (URICORI) Trial | November 24, 2020 | February 1, 2022 |
| NCT01775098 | Withdrawn | N/A | Allopurinol in Acute Gout | February 2013 |
- Disase is a (Disease Ontology)
- DOID:848
- Cross Reference ID (Disease Ontology)
- EFO:0004274
- Cross Reference ID (Disease Ontology)
- ICD10CM:M10
- Cross Reference ID (Disease Ontology)
- ICD9CM:274
- Cross Reference ID (Disease Ontology)
- ICD9CM:274.0
- Cross Reference ID (Disease Ontology)
- MESH:D006073
- Cross Reference ID (Disease Ontology)
- MESH:D015210
- Cross Reference ID (Disease Ontology)
- NCI:C34650
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:201661008
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:90560007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0003868
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0018099
- Exact Synonym (Disease Ontology)
- Articular gout
- Exact Synonym (Disease Ontology)
- gouty arthritis
- Exact Synonym (Disease Ontology)
- Gouty arthropathy
- HPO alt_id (Human Phenotype Ontology)
- HP:0001368
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0001997
- MedGen concept unique identifier (MedGen Concept name)
- C0018099
- MedGen unique identifier (MedGen Concept name)
- 42280
- ICD10 preferred id (Insert disease from ICD10)
- D0010301
- ICD10 class code (Insert disease from ICD10)
- M10
- MeSH unique ID (MeSH (Medical Subject Headings))
- D006073